MedTrace Logo

Circulating Tumor DNA as an Early Marker of Recurrence and Treatment Efficacy in Ovarian Carcinoma

NCT03302884 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2019-09-26

No results posted yet for this study

Summary

Prospective multicentre assay to assess ctDNA value for ovarian cancer monitoring and disease recurrence after front-line treatment.

Conditions

  • Ovarian Carcinoma

Interventions

OTHER

biological sampling

Tumor and blood samples

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Institut Paoli-Calmettes

    lead OTHER

Principal Investigators

  • Renaud SABATIER, MD · Institut Paoli-Calmettes

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-10
Primary Completion
2023-10-30
Completion
2023-10-30

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03302884 on ClinicalTrials.gov